Karyopharm Therapeutics Inc.: 5%+ holders

As of November 10, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Karyopharm Therapeutics Inc. The largest reported stake is RA Capital Management, L.P.'s, at 9.9%. 33 filings are on record since July 16, 2025 (Schedule 13G/A, August 14, 2026).

J. Wood Capital Advisors LLC also filed stake reports on 1 other company ↓

Sell to companies like Karyopharm Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-09 · Reporting person: The Goldman Sachs Group, Inc. · Sole voting: 0 · Shared voting: 203,126 · Sole dispositive: 0 · Shared dispositive: 203,129 · SCHEDULE 13G/A, 2026-11-09
• Filing 2026-10-28 · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 42,888 · Sole dispositive: 0 · Shared dispositive: 42,888 · SCHEDULE 13G/A, 2026-10-28
• Filing 2026-10-08 · Reporting person: Acorn Bioventures, L.P. · Sole voting: 0 · Shared voting: 429,101 · Sole dispositive: 0 · Shared dispositive: 429,101 · SCHEDULE 13G/A, 2026-10-08
• Filed 2026-09-25 · Holder: Anders Hove · Percent: 5.7% · SCHEDULE 13G/A
• Filed 2026-09-25 · Holder: Anders Hove · Percent: 5.7% · SCHEDULE 13G/A

Karyopharm Therapeutics Inc. has 33 Schedule 13D or 13G filings on record since 2025-07-16. 5 holders' latest filing reports 5% or more of common stock, par value $$0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Karyopharm Therapeutics Inc. and the warning signs.

See Karyopharm Therapeutics Inc.'s free Snapshot Watch Karyopharm Therapeutics Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Karyopharm Therapeutics Inc. and the records around it.

Karyopharm Therapeutics Inc. elsewhere on the record

• Bankruptcy record
• Who owns it

Companies that share a holder

• J. Wood Capital Advisors LLC also filed stake reports on 1 other company: Cyclerion Therapeutics, Inc. (Oct 2026)
• ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies: Athira Pharma, Inc. (Aug 2026), enGene Therapeutics Inc. (Jul 2026), OnKure Therapeutics, Inc. (Apr 2026)
• Opaleye Management Inc. also filed stake reports on 12 other companies: Codexis, Inc. (Nov 2026), Gossamer Bio, Inc. (Nov 2026), Pasithea Therapeutics Corp. (Nov 2026)

Want the whole picture on Karyopharm Therapeutics Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Karyopharm Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Karyopharm Therapeutics Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   35 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Karyopharm Therapeutics Inc. by CUSIP 48576U205 and gives its principal executive office as 85 WELLS AVENUE, 2ND FLOOR, NEWTON (SCHEDULE 13G/A, 2026-11-09).

What the percentages are based on

Due to the Beneficial Ownership Blocker listed in the Warrants, each Reporting Person's beneficial ownership percentage was 9.99% as of June 30, 2026.RA Capital Management, L.P., SCHEDULE 13G/A, 2026-08-14

The percentages set forth herein are calculated based upon 22,681,460 shares of Common Stock outstanding as of June 30, 2026 as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 filed with the Securities and Exchange Commission on August 13, 2026.Anders Hove, SCHEDULE 13G/A, 2026-10-08

Timeline

Swipe the table sideways to see every column.

Questions about who owns Karyopharm Therapeutics Inc.

Who owns Karyopharm Therapeutics Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of Karyopharm Therapeutics Inc.: RA Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-08-14), Affinity Asset Advisors, LLC (8.6%, Schedule 13G/A, filed 2026-05-14), Adage Capital Management, L.P. (6.78%, Schedule 13G/A, filed 2026-08-12), T. Rowe Price Investment Management, Inc. (6.6%, Schedule 13G/A, filed 2026-06-05) and BlackRock, Inc. (5.6%, Schedule 13G, filed 2026-07-28).

Who are the largest shareholders of Karyopharm Therapeutics Inc.?

By the share each holder's latest filing reports, the largest holders of Karyopharm Therapeutics Inc. on this page are RA Capital Management, L.P. (9.9%), Affinity Asset Advisors, LLC (8.6%) and Adage Capital Management, L.P. (6.78%).

When did RA Capital Management, L.P. buy into Karyopharm Therapeutics Inc.?

The filings give report dates, not purchase dates. The earliest filing from RA Capital Management, L.P. on this page is the Schedule 13G, filed 2026-04-02, reporting 9.9%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.9%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 33 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Karyopharm Therapeutics Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Karyopharm Therapeutics Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Karyopharm Therapeutics Inc. is mentioned again
• Find former Karyopharm Therapeutics Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes